TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
Employees - 1,
CEO - Dr. James A. Bianco M.D.,
Sector - Healthcare,
Country - US,
Market Cap - 148.52M
Altman ZScore(max is 10): -24.57, Piotroski Score(max is 10): 2, Working Capital: $1226000, Total Assets: $4140000, Retained Earnings: $-162052000, EBIT: -7819019, Total Liabilities: $2445000, Revenue: $0
AryaFin Target Price - $0.01 - Current Price $3.40 - Analyst Target Price $10.75
| Ticker | HURA |
| Index | - |
| Curent Price | 3.40 |
| Change | -2.30% |
| Market Cap | 148.52M |
| Average Volume | 232.99K |
| Income | -8.50M |
| Sales | 0.00M |
| Book Value/Share | -4.11 |
| Cash/Share | 0.11 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 11 |
| Moving Avg 20days | 13.69% |
| Moving Avg 50days | -1.28% |
| Moving Avg 200days | -39.82% |
| Shares Outstanding | 43.68M |
| Earnings Date | Apr 01 BMO |
| Inst. Ownership | 4.95% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | - |
| Price/Cash | 30.25 |
| Price/FCF | - |
| Quick Ratio | 2.45 |
| Current Ratio | 2.45 |
| Debt/Equity | 0.00 |
| Return on Assets | -163.44% |
| Return on Equity | -370.77% |
| Return on Investment | -226.27% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 52.96 |
| BETA(β) | 0.55 |
| From 52week Low | 88.89% |
| From 52week High | -76.70% |
| EPS | -75.23 |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | 71.02% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | 77.15% |
| Sales Y/Y | - |
| EPS Q/Q | 97.87% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | - |
| ATR(14) | 0.42 |
| Perf Week | -6.08% |
| Perf Month | 61.14% |
| Perf Quarter | -16.87% |
| Perf Year | -3.24% |
| Perf YTD | -16.87% |
| Target Price | 10.75 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer